tACS to Enhance Language Abilities

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorUniversity of Pennsylvania

About this trial

The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and sham tACS in conjunction with various language tests. Researchers will compare the post-stroke aphasia group with aged matched controls to see if brain response to tACS differs between groups.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Presence of aphasia

Suffered a single, left hemisphere stroke

Stroke ≥6 months old (chronic) at the time of enrollment

Right-handedness

Disqualifiers

Inability to understand the nature of the study

Marked naming impairment

Impaired non-verbal, conceptual processing

History of significant medical or neurological disorder (other than stroke)

Trial design

Design model

Crossover

Treatments tested in this trial

  • Active transcranial alternating current stimulation (tACS)

    Device

    Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: real-tACSActive comparator 1 intervention
Group B: sham-tACSPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Performance on the Blocked-Cyclic Naming (BCN) Task

The BCN tasks involves naming a set of pictures repeatedly. Sets of pictures come from either the same semantic category (high competition condition; e.g., categorically related: "dog", "cat", "panda") or different semantic categories (low competition condition; e.g., unrelated: dog, eye, crib).

Time frame
5-10 minutes after a single session of active (alpha tACS) and sham (fake tACS).

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.